Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
OHSU Knight Cancer Institute
Texas Oncology Cancer Center
OHSU Knight Cancer Institute